TIDMORPH
RNS Number : 1989V
Open Orphan PLC
10 December 2021
10 December 2021
Open Orphan plc
("Open Orphan" or the "Company")
$13.4m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in vaccine
and antiviral testing using human challenge clinical trials ,
announces that hVIVO , a subsidiary of Open Orphan plc, has signed
a $13.4m contract with a US-based biotechnology company to test its
novel antiviral candidate using the hVIVO Influenza Human Challenge
Study Model.
The study is expected to commence in H2 2022 and will be
conducted at hVIVO's state-of-the-art quarantine facilities in
London. The Company expect the majority of revenues to be
recognised in 2022.
The Company expects to sign an increasing number of contracts in
this area as the global pandemic has highlighted the increased
investment needed from governments and Big Pharma to develop
effective, novel treatments for a range of infectious diseases that
have potential to cause the next pandemic. Influenza is one such
disease, with emergences of flu pandemics impossible to predict.
Symptoms of influenza may be mild or cause severe disease, or in
certain cases, death. Influenza is a serious global health threat
with an estimated 1 billion cases per year, 3-5 million severe
cases and 290,000 - 650,000 deaths per year.
hVIVO has two decades of experience and expertise in safely
conducting challenge studies across a range of respiratory viruses,
including various strains of influenza, respiratory syncytial virus
(RSV), human rhinovirus (HRV - common cold virus), malaria, and
asthma. In October 2020, this expanded to include the SARS-CoV-2
virus.
Cathal Friel, Executive Chairman of Open Orphan, said : " We are
delighted to announce this significant challenge study contract
valued at over GBP10m, with a US-based biotechnology client testing
its highly promising influenza antiviral candidate. This contract
demonstrates the Company's continued ability to convert its leading
portfolio of challenge study models into substantial contracts,
with signed contracts across a number of our challenge study models
including RSV, asthma, hRV, and flu in the clinic next year. This
underlines our market position as the world leader in the testing
of vaccines, antivirals and respiratory products using human
challenge trials.
"The recent emergence of the Omicron variant has illustrated the
threat of pandemic infectious diseases, and as a result, pharma
companies globally are looking to address the next cohort of
infectious diseases which have potential to reach pandemic level,
and are developing new therapeutics to help tackle them. Influenza
is high on this list, and we expect to sign more contracts of this
type as the infectious disease market grows exponentially in the
coming years to be worth $250 billion by 2025. "
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 (as implemented into
English law) ("MAR"). With the publication of this announcement via
a Regulatory Information Service, this inside information is now
considered to be in the public domain.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
Individuals interested in taking part in COVID-19 human
challenge study research can learn more at www.UKCovidChallenge.com
.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR +44 (0)20 7933 8780 or openorphan@walbrookpr.com
& IR)
Paul McManus/ Sam Allen/ Louis Ashe-Jepson +44 (0)7980 541 893 / +44 (0) 7502
558 258 / +44 (0) 7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
vaccines and antivirals using human challenge clinical trials. The
Company provides services to Big Pharma, biotech and
government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. The Company has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of new models. There has been
an explosion in the growth of the infectious disease market, which
is estimated to grow to in excess of $250bn by 2025. The Group is
focused on refreshing its existing challenge models and develop new
models, such as Malaria, to address the dramatic growth potential
of the global infectious disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPGMGPUPGGRB
(END) Dow Jones Newswires
December 10, 2021 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024